Advances and challenges of CAR T therapy and suitability of animal models (Review)
- Authors:
- Xavier E. Ramos-Cardona
- Weichuan Luo
- Sulma I. Mohammed
-
Affiliations: Department of Comparative Pathobiology, Purdue University Center for Cancer Research, West Lafayette, IN 47907, USA, Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA - Published online on: July 12, 2022 https://doi.org/10.3892/mco.2022.2567
- Article Number: 134
-
Copyright: © Ramos-Cardona et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Wang Z, Guo Y and Han W: Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein Cell. 8:896–925. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Pilones KA, Aryankalayil J and Demaria S: Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clin Dev Immunol. 2012(720803)2012.PubMed/NCBI View Article : Google Scholar | |
|
Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al: The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 21:938–945. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Y, Niu C and Cui J: Gamma-delta (γδ) T cells: Friend or foe in cancer development? J Transl Med. 16(3)2018.PubMed/NCBI View Article : Google Scholar | |
|
Chmielewski M and Abken H: TRUCKs: The fourth generation of CARs. Expert Opin Biol Ther. 15:1145–1154. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Izsvák Z, Hackett PB, Cooper LJN and Ivics Z: Translating sleeping beauty transposition into cellular therapies: Victories and challenges. Bioessays. 32:756–767. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Zheng PP, Kros JM and Li J: Approved CAR T cell therapies: Ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today. 23:1175–1182. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al: Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 378:439–448. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al: Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 377:2531–2544. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, et al: Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 380:45–56. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Mullard A: FDA approves fourth CAR-T cell therapy. Nat Rev Drug Discov. 20(166)2021.PubMed/NCBI View Article : Google Scholar | |
|
Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M and Kobold S: Teaching an old dog new tricks: Next-generation CAR T cells. Br J Cancer. 120:26–37. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Charrot S and Hallam S: CAR-T Cells: Future perspectives. Hemasphere. 3(e188)2019.PubMed/NCBI View Article : Google Scholar | |
|
Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F and Kurosawa Y: Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 149:960–968. 1987.PubMed/NCBI View Article : Google Scholar | |
|
Ramos CA and Dotti G: Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 11:855–873. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Dotti G, Gottschalk S, Savoldo B and Brenner MK: Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 257:107–126. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Sharpe AH and Abbas AK: T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med. 355:973–975. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Zhang C, Liu J, Zhong JF and Zhang X: Engineering CAR-T cells. Biomark Res. 5(22)2017.PubMed/NCBI View Article : Google Scholar | |
|
Fesnak AD, June CH and Levine BL: Engineered T cells: The promise and challenges of cancer immunotherapy. Nat Rev Cancer. 16:566–581. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Chmielewski M, Hombach AA and Abken H: Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 257:83–90. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M and Brentjens RJ: Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 119:4133–4141. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Hunter BD and Jacobson CA: CAR T-Cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 111:646–654. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Sun S, Hao H, Yang G, Zhang Y and Fu Y: Immunotherapy with CAR-Modified T Cells: Toxicities and overcoming strategies. J Immunol Res. 2018(2386187)2018.PubMed/NCBI View Article : Google Scholar | |
|
Yáñez L, Sánchez-Escamilla M and Perales MA: CAR T cell toxicity: Current management and future directions. Hemasphere. 3(e186)2019.PubMed/NCBI View Article : Google Scholar | |
|
Fucà G, Reppel L, Landoni E, Savoldo B and Dotti G: Enhancing chimeric antigen receptor T-cell efficacy in solid tumors. Clin Cancer Res. 26:2444–2451. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z and Qian Q: Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 15:2548–2560. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Davila ML and Brentjens RJ: CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 14:802–808. 2016.PubMed/NCBI | |
|
Dotti G: The other face of chimeric antigen receptors. Mol Ther. 22:899–900. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Hombach A, Hombach AA and Abken H: Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Ther. 17:1206–1213. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Lee YG, Marks I, Srinivasarao M, Kanduluru AK, Mahalingam SM, Liu X, Chu H and Low PS: Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors. Cancer Res. 79:387–396. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Darowski D, Kobold S, Jost C and Klein C: Combining the best of two worlds: Highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. mAbs. 11:621–631. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Arndt C, Fasslrinner F, Loureiro LR, Koristka S, Feldmann A and Bachmann M: Adaptor CAR platforms-next generation of T Cell-based cancer immunotherapy. Cancers (Basel). 12(1302)2020.PubMed/NCBI View Article : Google Scholar | |
|
Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, et al: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 13(30)2020.PubMed/NCBI View Article : Google Scholar | |
|
Chen N, Morello A, Tano Z and Adusumilli PS: CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. Oncoimmunology. 6(e1273302)2016.PubMed/NCBI View Article : Google Scholar | |
|
Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y and June CH: Dominant-Negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 26:1855–1866. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Makita S, Yoshimura K and Tobinai K: Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci. 108:1109–1118. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 371:1507–1517. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Reagan PM and Friedberg JW: Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Future Oncol. 17:1269–1283. 2021.PubMed/NCBI View Article : Google Scholar | |
|
FDA approves second CAR T-cell therapy. Cancer Discov. 8:5–6. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Mullard A: FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 20(332)2021.PubMed/NCBI View Article : Google Scholar | |
|
Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR and Jelinek DF: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood. 103:689–694. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Ribas A and Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science. 359:1350–1355. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Guedan S, Ruella M and June CH: Emerging cellular therapies for cancer. Annu Rev Immunol. 37:145–171. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al: Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 375:2561–2569. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al: Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 118:6050–6056. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Vignali D and Kallikourdis M: Improving homing in T cell therapy. Cytokine Growth Factor Rev. 36:107–116. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Martinez M and Moon EK: CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 10(128)2019.PubMed/NCBI View Article : Google Scholar | |
|
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Richman SA, Nunez-Cruz S, Moghimi B, Li LZ, Gershenson ZT, Mourelatos Z, Barrett DM, Grupp SA and Milone MC: High-Affinity GD2-Specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol Res. 6:36–46. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Chang SS: Overview of prostate-specific membrane antigen. Rev Urol. 6 (Suppl 10):S13–S18. 2004.PubMed/NCBI | |
|
Hassan R and Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer. 44:46–53. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Fitzgerald AA and Weiner LM: The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 39:783–803. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Hammarström S: The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 9:67–81. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:707–712. 1989.PubMed/NCBI View Article : Google Scholar | |
|
Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19:1423–1437. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V and Wu L: Hypoxia selectively impairs CAR-T cells in vitro. Cancers (Basel). 11(602)2019.PubMed/NCBI View Article : Google Scholar | |
|
Oliver AJ, Lau PKH, Unsworth AS, Loi S, Darcy PK, Kershaw MH and Slaney CY: Tissue-Dependent tumor microenvironments and their impact on immunotherapy responses. Front Immunol. 9(70)2018.PubMed/NCBI View Article : Google Scholar | |
|
Newick K, O'Brien S, Moon E and Albelda SM: CAR T cell therapy for solid tumors. Annu Rev Med. 68:139–152. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, et al: A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 12(20 Pt 1):6106–6115. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q, Wang Y, Jia H and Han W: Phase I study of chimeric antigen receptor modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res. 24:1277–1286. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Lee JH and Lee SW: The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches. Gastroenterol Res Pract. 2017(7521987)2017.PubMed/NCBI View Article : Google Scholar | |
|
Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, et al: Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res. 21:3149–3159. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Paoloni M and Khanna C: Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 8:147–156. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JI, Culp WTN, Sparger EE, Rebhun RB, Monjazeb AM, et al: Canine cancer immunotherapy studies: Linking mouse and human. J Immunother Cancer. 4(97)2016.PubMed/NCBI View Article : Google Scholar | |
|
Mata M, Vera JF, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM and Gottschalk S: Toward immunotherapy with redirected T cells in a large animal model: Ex vivo activation, expansion, and genetic modification of canine T cells. J Immunother. 37:407–415. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Taraseviciute A, Tkachev V, Ponce R, Turtle CJ, Snyder JM, Liggitt HD, Myerson D, Gonzalez-Cuyar L, Baldessari A, English C, et al: Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 8:750–763. 2018.PubMed/NCBI View Article : Google Scholar | |
|
van Steenbeek FG, Hytönen MK, Leegwater PA and Lohi H: The canine era: The rise of a biomedical model. Anim Genet. 47:519–527. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Abadie J, Nguyen F, Loussouarn D, Pena L, Gama A, Rieder N, Belousov A, Bemelmans I, Jaillardon L, Ibisch C and Campone M: Canine invasive mammary carcinomas as models of human breast cancer. Part 2: Immunophenotypes and prognostic significance. Breast Cancer Res Treat. 167:459–468. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Queiroga FL, Raposo T, Carvalho MI, Prada J and Pires I: Canine mammary tumours as a model to study human breast cancer: Most recent findings. In Vivo. 25:455–465. 2011.PubMed/NCBI | |
|
Buishand FO, Kik M and Kirpensteijn J: Evaluation of clinico-pathological criteria and the Ki67 index as prognostic indicators in canine insulinoma. Vet J. 185:62–67. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Siobhan S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP and Rutland CS: Comparative review of human and canine osteosarcoma: Morphology, epidemiology, prognosis, treatment and genetics. Acta Vet Scand. 59(71)2017.PubMed/NCBI View Article : Google Scholar | |
|
Leroy BE and Northrup N: Prostate cancer in dogs: Comparative and clinical aspects. Vet J. 180:149–162. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Sun F, Báez-Díaz C and Sánchez-Margallo FM: Canine prostate models in preclinical studies of minimally invasive interventions: Part I, canine prostate anatomy and prostate cancer models. Transl Androl Urol. 6:538–546. 2017.PubMed/NCBI View Article : Google Scholar | |
|
McEntee M, Isaacs W and Smith C: Adenocarcinoma of the canine prostate: Immunohistochemical examination for secretory antigens. Prostate. 11:163–170. 1987.PubMed/NCBI View Article : Google Scholar | |
|
Sorenmo KU, Goldschmidt M, Shofer F, Goldkamp C and Ferracone J: Immunohistochemical characterization of canine prostatic carcinoma and correlation with castration status and castration time. Vet Comp Oncol. 1:48–56. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Yu H, Pan J, Guo Z, Yang C and Mao L: CART cell therapy for prostate cancer: Status and promise. Onco Targets Ther. 12:391–395. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Hillerdal V, Nilsson B, Carlsson B, Eriksson F and Essand M: T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells. Proc Natl Acad Sci USA. 109:15877–15881. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, Bachmann M, Abken H, Rieber EP and Temme A: Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate. 67:1121–1131. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Fulkerson CM, Dhawan D, Ratliff TL, Hahn NM and Knapp DW: Naturally occurring canine invasive urinary bladder cancer: A complementary animal model to improve the success rate in human clinical trials of new cancer drugs. Int J Genomics. 2017(6589529)2017.PubMed/NCBI View Article : Google Scholar | |
|
Ma Q, Gomes EM, Lo AS and Junghans RP: Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Prostate. 74:286–296. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Knapp DW, Ramos-Vara JA, Moore GE, Dhawan D, Bonney PL and Young KE: Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. ILAR J. 55:100–118. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Dhawan D, Paoloni M, Shukradas S, Choudhury DR, Craig B, Ramos-Vara JA, Hahn N, Bonney PL, Khanna C and Knapp DW: Comparative gene expression analyses identify luminal and basal subtypes of canine invasive urothelial carcinoma that mimic patterns in human invasive bladder cancer. PLoS One. 10(e0136688)2015.PubMed/NCBI View Article : Google Scholar | |
|
Panjwani MK, Smith JB, Schutsky K, Gnanandarajah J, O'Connor CM, Powell DJ Jr and Mason NJ: Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Mol Ther. 24:1602–1614. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Panjwani MK, Atherton MJ, MaloneyHuss MA, Haran KP, Xiong A, Gupta M, Kulikovsaya I, Lacey SF and Mason NJ: Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. OncoImmunology. 9(1676615)2019.PubMed/NCBI View Article : Google Scholar |
